Literature DB >> 12023992

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Noah D Kauff1, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat, Larry Norton, Mercedes Castiel, Khedoudja Nafa, Kenneth Offit.   

Abstract

BACKGROUND: Risk-reducing salpingo-oophorectomy is often considered by carriers of BRCA mutations who have completed childbearing. However, there are limited data supporting the efficacy of this approach. We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations.
METHODS: All women with BRCA1 or BRCA2 mutations identified during a six-year period were offered enrollment in a prospective follow-up study. A total of 170 women 35 years of age or older who had not undergone bilateral oophorectomy chose to undergo either surveillance for ovarian cancer or risk-reducing salpingo-oophorectomy. Follow-up involved an annual questionnaire, telephone contact, and reviews of medical records. The time to cancer in the two groups was compared by Kaplan-Meier analysis and a Cox proportional-hazards model.
RESULTS: During a mean follow-up of 24.2 months, breast cancer was diagnosed in 3 of the 98 women who chose risk-reducing salpingo-oophorectomy and peritoneal cancer was diagnosed in 1 woman in this group. Among the 72 women who chose surveillance, breast cancer was diagnosed in 8, ovarian cancer in 4, and peritoneal cancer in 1. The time to breast cancer or BRCA-related gynecologic cancer was longer in the salpingo-oophorectomy group, with a hazard ratio for subsequent breast cancer or BRCA-related gynecologic cancer of 0.25 (95 percent confidence interval, 0.08 to 0.74).
CONCLUSIONS: Salpingo-oophorectomy in carriers of BRCA mutations can decrease the risk of breast cancer and BRCA-related gynecologic cancer.

Entities:  

Mesh:

Year:  2002        PMID: 12023992     DOI: 10.1056/NEJMoa020119

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  271 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Breast cancer prevention.

Authors:  Kefah Mokbel
Journal:  Br J Gen Pract       Date:  2002-12       Impact factor: 5.386

3.  Participating in primary care research.

Authors:  Robert K McKinley; Mary Dixon-Woods; Hazel Thornton
Journal:  Br J Gen Pract       Date:  2002-12       Impact factor: 5.386

4.  Presumption, privilege, and preemption.

Authors:  Murray F Brennan
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

Review 5.  Cancer biomarkers.

Authors:  N Lynn Henry; Daniel F Hayes
Journal:  Mol Oncol       Date:  2012-02-06       Impact factor: 6.603

6.  Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.

Authors:  Janie M Lee; Pamela M McMahon; Chung Y Kong; Daniel B Kopans; Paula D Ryan; Elissa M Ozanne; Elkan F Halpern; G Scott Gazelle
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

7.  Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.

Authors:  Laura L Holman; Sue Friedman; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

Review 8.  Management updates for women with a BRCA1 or BRCA2 mutation.

Authors:  Rachel Nusbaum; Claudine Isaacs
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.

Authors:  Murray Joseph Casey; Todd A Salzman
Journal:  Linacre Q       Date:  2018-07-20

10.  Breast cancer gene variants: separating the harmful from the harmless.

Authors:  Susan M Domchek; Roger A Greenberg
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.